We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
UnitedHealth (UNH) to Post Q2 Earnings: What to Expect?
Read MoreHide Full Article
UnitedHealth Group Incorporated (UNH - Free Report) is set to report second-quarter 2022 results on Jul 15, before the opening bell.
The healthcare plan provider reported adjusted earnings of $5.49 per share for the first quarter, beating the Zacks Consensus Estimate of $5.40 on the back of strong performances in UnitedHealthcare and Optum businesses. An increased number of people served by UnitedHealthcare and solid growth in comprehensive managed services in Optum sub-segments aided the results.
The Zacks Consensus Estimate for second-quarter earnings per share of $5.24 suggests an 11.5% increase from the prior-year figure of $4.70. The earnings estimate remained stable over the past week. The consensus estimate for second-quarter revenues of $79.6 billion indicates an 11.6% increase from the year-ago reported figure.
UnitedHealth beat the consensus estimate for earnings in each of the prior four quarters, with the average being 3.7%. This is depicted in the graph below:
UnitedHealth Group Incorporated Price and EPS Surprise
UnitedHealth’s second-quarter results are expected to be boosted by higher premiums. The Zacks Consensus Estimate for revenues from premiums is pegged at $63,110 million, indicating an increase from $56,233 million a year ago. Solid insurance sales of dental and vision plans might have aided premium growth. Also, the consensus mark for products is pegged at $9,381 million, signaling a jump from $8,433 million a year ago.
Revenues from UnitedHealthcare, UNH’s largest segment that sells insurance, are likely to have risen on higher membership in the community and senior programs. The Zacks Consensus Estimate for services is pegged at $6,717 million, indicating an increase from the year-ago figure of $6,099 million. As such, the consensus mark for revenues in UnitedHealthcare indicates 9.4% growth from the year-ago period.
The Optum business segment is expected to have witnessed a higher contribution from sub-segments, OptumHealth and Optum Insight, in the second quarter. A rise in the number of people being catered to in value-based care arrangements and the growing strength of affiliated physicians might aid the results. Optum Insight is likely to have witnessed higher profits owing to growth in services and technology offerings and improved productivity.
The Zacks Consensus Estimate for operating income from the Optum business is pegged at $3,339 million, signaling a jump from $2,883 million in the prior-year quarter. This might have led to a year-over-year rise in the bottom line.
However, UnitedHealth is likely to have faced an elevated expense level due to a rise in medical and operating costs. Higher costs of products sold are likely to have reduced its margins. This might have affected its profit levels in the second quarter, making an earnings beat uncertain.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for UnitedHealth this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. That is not the case here, as you will see below.
Earnings ESP: The company’s Earnings ESP is 0.00%. This is because the Most Accurate Estimate currently stands at $5.24 per share, in line with the Zacks Consensus Estimate.
You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: UnitedHealth currently carries a Zacks Rank #3.
Stocks to Consider
While an earnings beat looks uncertain for UnitedHealth, here are some companies from the Medical space that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this time around:
Affimed N.V. (AFMD - Free Report) has an Earnings ESP of +16.67% and a Zacks Rank #2.
The Zacks Consensus Estimate for Affimed’s bottom line for the to-be-reported quarter indicates a 5.3% improvement from the year-ago period. AFMD witnessed four upward estimate revisions in the past 60 days compared with one in the opposite direction.
Centene Corporation (CNC - Free Report) has an Earnings ESP of +1.42% and is a Zacks #3 Ranked player.
The Zacks Consensus Estimate for Centene’s earnings per share for the to-be-reported quarter is pegged at $1.69, implying a 35.2% improvement from the year-ago figure. CNC witnessed five upward estimate revisions in the past 30 days compared with none in the opposite direction.
Elevance Health Inc. (ELV - Free Report) has an Earnings ESP of +0.43% and is a Zacks #3 Ranked player.
The Zacks Consensus Estimate for Elevance Health’s bottom line for the to-be-reported quarter indicates a 10% jump from a year ago. The consensus mark for ELV’s top line indicates a 14.6% year-over-year increase.
Image: Bigstock
UnitedHealth (UNH) to Post Q2 Earnings: What to Expect?
UnitedHealth Group Incorporated (UNH - Free Report) is set to report second-quarter 2022 results on Jul 15, before the opening bell.
The healthcare plan provider reported adjusted earnings of $5.49 per share for the first quarter, beating the Zacks Consensus Estimate of $5.40 on the back of strong performances in UnitedHealthcare and Optum businesses. An increased number of people served by UnitedHealthcare and solid growth in comprehensive managed services in Optum sub-segments aided the results.
Let’s see how things have shaped up before the second-quarter earnings announcement.
Trend in Estimate Revision
The Zacks Consensus Estimate for second-quarter earnings per share of $5.24 suggests an 11.5% increase from the prior-year figure of $4.70. The earnings estimate remained stable over the past week. The consensus estimate for second-quarter revenues of $79.6 billion indicates an 11.6% increase from the year-ago reported figure.
UnitedHealth beat the consensus estimate for earnings in each of the prior four quarters, with the average being 3.7%. This is depicted in the graph below:
UnitedHealth Group Incorporated Price and EPS Surprise
UnitedHealth Group Incorporated price-eps-surprise | UnitedHealth Group Incorporated Quote
Factors to Note
UnitedHealth’s second-quarter results are expected to be boosted by higher premiums. The Zacks Consensus Estimate for revenues from premiums is pegged at $63,110 million, indicating an increase from $56,233 million a year ago. Solid insurance sales of dental and vision plans might have aided premium growth. Also, the consensus mark for products is pegged at $9,381 million, signaling a jump from $8,433 million a year ago.
Revenues from UnitedHealthcare, UNH’s largest segment that sells insurance, are likely to have risen on higher membership in the community and senior programs. The Zacks Consensus Estimate for services is pegged at $6,717 million, indicating an increase from the year-ago figure of $6,099 million. As such, the consensus mark for revenues in UnitedHealthcare indicates 9.4% growth from the year-ago period.
The Optum business segment is expected to have witnessed a higher contribution from sub-segments, OptumHealth and Optum Insight, in the second quarter. A rise in the number of people being catered to in value-based care arrangements and the growing strength of affiliated physicians might aid the results. Optum Insight is likely to have witnessed higher profits owing to growth in services and technology offerings and improved productivity.
The Zacks Consensus Estimate for operating income from the Optum business is pegged at $3,339 million, signaling a jump from $2,883 million in the prior-year quarter. This might have led to a year-over-year rise in the bottom line.
However, UnitedHealth is likely to have faced an elevated expense level due to a rise in medical and operating costs. Higher costs of products sold are likely to have reduced its margins. This might have affected its profit levels in the second quarter, making an earnings beat uncertain.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for UnitedHealth this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. That is not the case here, as you will see below.
Earnings ESP: The company’s Earnings ESP is 0.00%. This is because the Most Accurate Estimate currently stands at $5.24 per share, in line with the Zacks Consensus Estimate.
You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: UnitedHealth currently carries a Zacks Rank #3.
Stocks to Consider
While an earnings beat looks uncertain for UnitedHealth, here are some companies from the Medical space that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this time around:
Affimed N.V. (AFMD - Free Report) has an Earnings ESP of +16.67% and a Zacks Rank #2.
You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Affimed’s bottom line for the to-be-reported quarter indicates a 5.3% improvement from the year-ago period. AFMD witnessed four upward estimate revisions in the past 60 days compared with one in the opposite direction.
Centene Corporation (CNC - Free Report) has an Earnings ESP of +1.42% and is a Zacks #3 Ranked player.
The Zacks Consensus Estimate for Centene’s earnings per share for the to-be-reported quarter is pegged at $1.69, implying a 35.2% improvement from the year-ago figure. CNC witnessed five upward estimate revisions in the past 30 days compared with none in the opposite direction.
Elevance Health Inc. (ELV - Free Report) has an Earnings ESP of +0.43% and is a Zacks #3 Ranked player.
The Zacks Consensus Estimate for Elevance Health’s bottom line for the to-be-reported quarter indicates a 10% jump from a year ago. The consensus mark for ELV’s top line indicates a 14.6% year-over-year increase.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.